Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (IPF): A Randomized, Double-blind, Placebo-controlled, 52-week Dose-ranging Study

NCT02345070 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02345070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02345070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (IPF): A Randomized, Double-blind, Placebo-controlled, 52-week Dose-ranging Study
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
May 1, 2015
Completion date
August 14, 2017
Enrollment
327 (actual)
Sites
101

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis